

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC DIGOXIN AND DOXYCYCLINE
ANTITRUST LITIGATION

MDL No. 2724
Case No. 16-md-2724-CMR
Hon. Cynthia M. Rufe

DEFENDANT HERITAGE PHARMACEUTICALS INC.'S
RULE 7.1 CORPORATE DISCLOSURE STATEMENT

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, Defendant Heritage Pharmaceuticals Inc. (“Heritage”), by and through counsel, hereby states that Heritage is a wholly owned subsidiary of Heritage Pharmaceuticals Holdings Inc., which is a wholly owned subsidiary of Emcure Pharmaceuticals Ltd., an Indian corporation. Heritage is not a publicly traded entity, and no publicly held corporation holds 10% or more of any direct or indirect corporate parent of Heritage.

Dated: February 22, 2017

Respectfully submitted,

By: /s/ D. Jarrett Arp
D. Jarrett Arp
GIBSON, DUNN & CRUTCHER LLP
1050 Connecticut Ave., NW
Washington, DC 20036-5306
Telephone: (202) 955-8678
Facsimile: (202) 530-9527
jarp@gibsondunn.com

*Attorneys for Defendant Heritage
Pharmaceuticals Inc.*

CERTIFICATE OF SERVICE

I hereby certify that on February 22, 2017, the foregoing Rule 7.1 Corporate Disclosure Statement was served on all counsel of record via ECF. Pursuant to Local Rule 5.1.2(8)(b), I further certify that the foregoing document is available for viewing and downloading on ECF.

/s/ D. Jarrett Arp
D. Jarrett Arp